Eyenuk
PrivateLast Round
Seed Round
Apr 28, 2026
Total Funding Raised
$37.27M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Eyenuk operates in Healthcare & Life Sciences and is based in Los Angeles, California. Its latest recorded funding round was a Series A round in October 2022.
Eyenuk is a healthcare technology company that specializes in artificial intelligence-driven eye screening solutions for autonomous disease detection and risk assessment.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Imaging, Computer Vision, EHR & EMR
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eyenuk Comparables
Compare Eyenuk with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| RETINA-AI Health | 91% | |
| Digital Diagnostics | 91% | |
| AEYE Health | 89% |
For institutional investors. Book with your work email.
Eyenuk Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Apr 28, 2026 | ||||
| Series A | Oct 17, 2022 | ||||
| Convertible Debt | Jul 20, 2021 | ||||
| Grant | Oct 10, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Eyenuk Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Kendall Capital Partners | Series A |
| KOFA Healthcare | Series A |
| NIH RADx | Grant |
| AXA IM Alts | Convertible Debt, Series A |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
| BNP Paribas Asset Management | Convertible Debt, Series A |
| National Institute of Neurological Disorders and Stroke | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 28, 2026
Raised $5.6M in seed funding.
- Jan 6, 2025
Gaurav Agarwal appointed as the new Chief Executive Officer.
For institutional investors. Book with your work email.
Eyenuk Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Eyenuk's valuation, stock price, and market status.
Is Eyenuk a public or private company?
Eyenuk is a private company.
What is the current stock price of Eyenuk?
Eyenuk is a private company, so its shares have no public market price. Caplight tracks Eyenuk's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Eyenuk worth (valuation)?
Valuation information for Eyenuk is not publicly available.
Can I buy Eyenuk stock?
Eyenuk shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Eyenuk's last funding round?
Eyenuk's most recent funding round was Seed Round on April 28, 2026.
Who are the main investors in Eyenuk?
Key investors in Eyenuk include AXA IM Alts, BNP Paribas Asset Management.
Will Eyenuk IPO soon?
No public IPO plans have been announced for Eyenuk.
How can I track Eyenuk secondary market activity?
Caplight tracks bids, offers, and trades in Eyenuk's shares on secondary markets.